hotspot -WSS

hotspot

author：hotspot 2025-10-01 21:34:29 - browse：37

Adam's take main illustration — Molly Ferguson/STAT

Thoughts about Cytokinetics after Wednesday night’s financing announcement:

1. Management is raising $500 million at $51 per share, when the stock was at $45 per share before the aficamtem study readout in December. That’s shocking. Somehow, management has not only removed all the M&A premium from the stock, but much or most of aficamtem’s value, too.

2. Omecamtiv’s resurrection: Are you kidding me? No one thinks bringing back this heart failure drug is a good idea, except management. Making it worse, the terms of the Royalty Pharma loan are, again, shocking. All the risk is borne by Cytokinetics. Royalty, in fact, may do better if omecamtiv fails.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus in-depth analysis, newsletters, premium events, and networking platform access.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Tori Bowie and the unacceptable rates of Black maternal death
Next article： Vertex non

WSS

FTC sues over Novant Health acquisition of two N.C. hospitals

Zyn nicotine pouches become unlikely player in latest culture war

Merck CEO won’t testify in Senate, citing no expertise in drug prices

FTC sues over Novant Health acquisition of two N.C. hospitals

Listen: Your guide to Wegovy's blockbuster heart study

Philips to halt sales of sleep apnea machines in U.S.

hotspot

hotspot

This article is exclusive to STAT+ subscribers

Unlock this article — plus in-depth analysis, newsletters, premium events, and networking platform access.

entertainment

How one medical school became remarkably diverse

TB outbreak tied to bone grafts underscores testing shortcomings

Supreme Court strikes down use of affirmative action

Philips to halt sales of sleep apnea machines in U.S.

Dobbs anniversary: the lost opportunity of abortion as health care

Medicare drug price negotiation legal challenge met with skepticism

After affirmative action ruling, medical educators look to 'holistic review'

Bernie Sanders is gearing up to subpoena pharma CEOs

Medical leaders decry Supreme Court decision on affirmative action

Faced with fears of OxyContin misuse, sales reps touted its safety

focus

GOP presidential candidates start declaring their loyalty

'Disease catastrophe' looms in Sudan as health conditions deteriorate, medics warn

Philips to halt sales of sleep apnea machines in U.S.

After John Oliver segment, STAT readers share their opioid

Humana’s losses in Medicare Advantage tank its stock

Zyn nicotine pouches become unlikely player in latest culture war

entertainment

hotspot

knowledge

Wikipedia